Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Horizon Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Rule 17(e) Announcement - Horizon Therapeutics plc
October 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 17(d) Announcement – Horizon Therapeutics plc
October 05, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
October 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
October 02, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
October 02, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
September 29, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
September 29, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
September 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
September 26, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
September 25, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
September 19, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
September 13, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
September 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
September 05, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
August 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc - Rule 2.12 Announcement
August 09, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
August 08, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
July 28, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
July 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
July 21, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
July 17, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
July 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
June 30, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
June 26, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
June 22, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
June 17, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
June 17, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
June 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
June 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
June 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.